Tiny packets shed by mitochondria may help spread Alzheimer's damage — in human tissue and mice

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Mitochondria do not just power the brain — they also mail out pieces of themselves. In Alzheimer's brains, more of those parcels are going out, and what they carry may be part of the problem.

What are mitovesicles, and what did the team find?

Mitovesicles (mtVs) are extracellular vesicles with a double membrane that carry mitochondrial contents, including mtDNA and mitochondrial proteins. Separating vesicle fractions from brain tissue, the team found mtV release significantly upregulated in the brains of Alzheimer's patients and of 5xFAD mice, and identified Ggt1 — gamma-glutamyltransferase 1, an enzyme that hydrolyzes glutathione — as a highly enriched protein in the Alzheimer's-derived vesicles, with cell experiments pointing to microglia, the brain's resident immune cells, as a source.

What happened when the vesicles were transferred?

Vesicles taken from 5xFAD brains and injected into healthy mice induced Alzheimer's-like phenotypes — impaired learning and memory, glial activation and inflammatory responses, and abnormalities of neuronal synaptic structure and function — while vesicles from healthy brains did not. Injected into Alzheimer's-model mice, they significantly accelerated disease progression. That transfer design is what elevates the finding from association toward mechanism, within the limits of a mouse model.

Could blocking the pathway help?

In the animal model, yes, on the study's own terms: Ggt1 genetic knockout or pharmacological inhibition significantly mitigated the Alzheimer's-like phenotypes and abrogated the vesicles' acceleration of pathology, and suppressing mtV release — by inhibiting fumarate hydratase or supplementing dimethyl fumarate/coenzyme Q10 — also alleviated phenotypes. None of that has been tested in patients. The human data show more vesicles and more Ggt1 in Alzheimer's tissue; whether blocking Ggt1 in the human brain would be safe, selective, or effective is entirely open.

Where the evidence stands

• Established: Mitochondrial changes are early and central pathological features of Alzheimer's disease; extracellular vesicles carry cargo between brain cells; Ggt1 breaks down glutathione, a key cellular antioxidant.
• Preliminary: The mitovesicle-Ggt1 pathway: one study (Nature Aging, 2026) combining observational human brain tissue comparisons with transfer, knockout and inhibitor experiments in 5xFAD mice. The mouse model captures amyloid features, not the whole of human Alzheimer's.
• Absent: Human interventional evidence — no trial has blocked Ggt1 or mitovesicle release in Alzheimer's patients, and the size of this pathway's contribution to human disease progression is unknown.